Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 79Carcinoma, Renal Cell 36Neoplasms 35Liver Neoplasms 22Carcinoma, Non-Small-Cell Lung 7Carcinoma 7Neoplasm Metastasis 6Melanoma 5Thyroid Neoplasms 4Kidney Neoplasms 4Breast Neoplasms 3Financial Stress 2Vaccinia 1Stomach Neoplasms 1Patient Preference 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoma 1Lung Neoplasms 1Liver Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulin-Like Growth Factor I, Resistance To 1Hypophosphatemia 1Hepatitis C 1Hepatitis B 1Glioblastoma 1Digestive System Neoplasms 1

Interventions

trebananib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Hepatocellular Carcinoma × Sorafenib × Clear all
NCT00872014 2016-04-04

A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Amgen

Phase 2 Completed
60 enrolled
Gastrointestinal

Advanced Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡